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ABSTRACT
Metabotropic glutamate receptors (mGluR) are predominantly involved in 
maintenance of cellular homeostasis of central nervous system. However, evidences 
have suggested other roles of mGluR in human tumors. Aberrant mGluR signaling 
has been shown to participate in transformation and maintenance of various cancer 
types, including malignant brain tumors. This review intends to summarize recent 
findings regarding the involvement of mGluR-mediated intracellular signaling 
pathways in progression, aggressiveness, and recurrence of malignant gliomas, 
mainly glioblastomas (GBM), highlighting the potential therapeutic applications of 
mGluR ligands. In addition to the growing number of studies reporting mGluR gene 
or protein expression in glioma samples (resections, lineages, and primary cultures), 
pharmacological blockade in vitro of mGluR1 and mGluR3 by selective ligands has been 
shown to be anti-proliferative and anti-migratory, decreasing activation of MAPK and 
PI3K pathways. In addition, mGluR3 antagonists promoted astroglial differentiation 
of GBM cells and also enabled cytotoxic action of temozolomide (TMZ). mGluR3-
dependent TMZ toxicity was supported by increasing levels of MGMT transcripts 
through an intracellular signaling pathway that sequentially involves PI3K and NF-
κB. Further, continuous pharmacological blockade of mGluR1 and mGluR3 have been 
shown to reduced growth of GBM tumor in two independent in vivo xenograft models. 
In parallel, low levels of mGluR3 mRNA in GBM resections may be a predictor for long 
survival rate of patients. Since several Phase I, II and III clinical trials are being 
performed using group I and II mGluR modulators, there is a strong scientifically-
based rationale for testing mGluR antagonists as an adjuvant therapy for malignant 
brain tumors.
INTRODUCTION
Gliomas are the most common type of primary brain 
tumor and are often fast growing with a poor prognosis 
for patient [1]. The World Health Organization (WHO) 
classified gliomas in 2016 using molecular parameters in 
addition to their histological and immunohistochemical 
resemblance to presumed cells of origin and graded them 
by increasing degrees of undifferentiation, anaplasia, 
and aggressiveness (i.e., mitotic figures, necrosis, and 
vascular endothelial hyperplasia) [2, 3]. High-grade 
gliomas represent 60-75% of all cases and include grade 
III anaplastic astrocytoma, anaplastic oligodendroglioma, 
mixed anaplastic oligoastrocytoma, and grade IV 
glioblastoma [4]. Glioblastoma (GBM) is the most 
common malignant primary brain tumor and is one of 
the most lethal human cancers [2, 5]. Recently, GBM 
was classified in three groups: (1) GBM, IDH-wildtype 
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Oncotarget22280www.impactjournals.com/oncotarget
(about 90% of cases, generally corresponds to the clinical 
definition of primary GBM and is prevalent in patients 
over 55 years); (2) GBM, IDH-mutant (about 10 % of 
cases, corresponds closely to so-called secondary GBM 
and preferentially arises in younger patients); and (3) 
GBM, NOS (a diagnosis that is reserved for those tumors 
for which full IDH evaluation cannot be performed) [3]. 
In United States, GBM accounts for 15.1% of all primary 
brain tumors, 46.1% of primary malignant brain tumors, 
and its annual incidence is 3.2 per 100,000 people (or 
10,787 new cases diagnosed per year) [6]. Even though 
GBM may develop at any age, it is more common in 
elderly with a higher incidence rate in ages between 75 
to 84 years (15.24 new cases per 100,000 people between 
these ages per year). In addition, GBM is 1.6 times more 
common in males and its incidence rate is 2 times higher 
among caucasians [6]. 
Regarding histology, GBM is characterized by 
considerable cellularity and mitotic activity, vascular 
proliferation, and necrosis [7]. Because GBM cells vary 
in size and shape, i.e., they are pleomorphic, this glioma 
was frequently called glioblastoma multiforme, a term no 
longer in use. From a molecular point of view, GBM is a 
highly heterogeneous tumor [8]. Genome-wide expression 
studies have revealed 4 transcriptional subclasses of 
GBM, displaying features reminiscent of distinct cell 
types: classical, mesenchymal, proneural, and neural [9, 
10]. Classical subclass typically displays chromosome 
7 amplifications, chromosome 10 deletions, EGFR 
amplification, EGFR mutations, and Ink4a/ARF locus 
deletion. Mesenchymal subclass displays a high frequency 
of NF1 mutation/deletion, high expression of CHI3L1, 
MET, and genes involved in tumor necrosis factor and 
nuclear factor-κB (NF-κB) pathways. Proneural GBM is 
characterized by alterations of PDGFRA and mutations 
in IDH1 and TP53, sharing gene expression features 
with low-grade gliomas and secondary GBM (i.e., low-
grade gliomas later recurred as GBM). Neural subclass is 
characterized by expression of neuronal markers. Many 
molecular abnormalities and mutations overlap across 
transcriptional subclasses, for example PTEN loss, and a 
large number of very rare mutations have been described 
[11, 12].
Although GBM is typically confined to Central 
Nervous System (CNS) and rarely performing metastases 
in distant organs, this and other malignant gliomas are 
highly invasive, infiltrating surrounding brain parenchyma 
[5]. After initial diagnosis, standard treatment for GBM 
consists of maximal surgical resection [13, 14]. This 
practice aims to relieve mass effect, achieve cytoreduction, 
and provide adequate tissue for histologic and molecular 
tumor characterization. Although surgical resection can 
greatly reduce tumor bulk, complete tumor excision is 
frequently not reached due to infiltrative nature of GBM 
cells [15]. After surgical resection, adjuvant radiotherapy 
combined with chemotherapy should be considered for 
all patients. A radiotherapy dose of 60 Gy is frequently 
used [13]. In addition, the DNA alkylating agent named 
temozolomide (TMZ) is orally administered as first-line 
chemotherapy [5, 16]. This regimen is supported by a 
randomized phase III study [17], which demonstrated 
TMZ increased median survival to 15 months versus 
12 months with radiotherapy alone (hazard ratio - HR 
= 0.63; P < .001). Two-year survival rate was also 
increased: 27% for chemotherapy plus radiotherapy 
versus 10% for radiotherapy alone [17]. Alternatively, 
biodegradable polymers containing the alkylating agent 
carmustine (BCNU) can be implanted into tumor bed 
after surgical resection. Nevertheless, a phase III trial 
has indicated a modest survival benefit of this regimen 
[18]. A humanized vascular endothelial growth factor 
(VEGF) monoclonal antibody named bevacizumab had 
been recently introduced as first-line monotherapy for 
progressive GBM [19]. Approval of bevacizumab by U.S. 
Food and Drug Administration was based on improvement 
of radiologic response rates observed in two single-arm 
or noncomparative phase II trials [20, 21]. However, two 
recent multicenter, phase III, randomized, double-blind, 
placebo-controlled trials [22, 23], have demonstrated 
bevacizumab increased median progression-free survival 
(10.6 vs. 6.2 months, HR: 0.64, p < 0.0001 [22]; 10.7 vs. 
7.3 months, HR: 0.79, p = 0.004 [23]) but not overall 
survival of patients (16-17 months).
Although radiotherapy and chemotherapy improve 
patient’s survival, GBM remains among the most lethal 
and resistant malignant tumor [2, 24], and recurrence 
is nearly universal after a median progression-free 
survival of 7 to 10 months [25]. Thus, development of 
new therapies targeting surface molecules or signaling 
pathways that specifically regulate GBM proliferation or 
differentiation seems necessary.
In this context, in the present review we summarized 
the recent evidences demonstrating the participation of 
mGluR-mediated signaling pathways in GBM proliferation 
and differentiation, highlighting the putative role of these 
receptors as new molecular target for management and 
treatment of this neoplasia.
GLUTAMATE AS A GROWTH FACTOR 
FOR GLIOBLASTOMA
Several in vitro and in vivo studies have 
demonstrated GBM cells can release high levels of 
glutamate (L-Glu) to extracellular fluid. Released L-Glu 
may act as a neurotrophic factor, promoting proliferation 
and migration of glioma cells as well as contributing to 
tumor malignancy [26-28]. L-Glu autocrine secretion 
occurs mainly by cystine-glutamate antiporter (xCT), 
which exchanges extracellular cystine (Cys) for 
intracellular L-Glu at a 1:1 stoichiometric ratio [27, 29] 
(Figure 1, step 1). Moreover, due to loss of excitatory 
amino acid transporter 2 (EAAT2), GBM cells possess 
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a low re-uptake rate of L-Glu from extracellular fluid, 
which keeps this aminoacid at a high concentration in 
extracellular fluid and increases tumor malignancy [27, 
30] (Figure 1, step 2). Furthermore, higher levels of L-Glu 
can trigger a mechanism of neuronal cell death called 
excitotoxicity [31], which facilitates tumor bulk expansion 
[27, 32-34] (Figure 1, step 3).
Extracellular L-Glu activates two classes of 
membrane receptors: ionotropic glutamate receptors 
(iGluR: AMPA, NMDA and Kainate receptors), which are 
Figure 1: Regulation of GBM proliferative pathways by metabotropic glutamate receptors (mGluR). (1) GBM cells 
can release low levels of L-Glu mainly by xCT antiporter [27, 28]. (2) Due to loss of EAAT2, GBM cells possessed a low re-uptake rate 
of L-Glu, maintaining high concentrations of this amino acid in tumor environment [30]. (3) High levels of L-Glu can activate specific 
NMDAR, which causes neuronal death by excitotoxicity and facilitates tumor bulk expansion [27]. (4) GBM cells expressing mutated 
Ca+2-permeable AMPAR exhibited enhanced migration and proliferation and its blockade led to inhibition of growth and induction of 
apoptosis [42]. (5) mGluR3 activation by L-Glu induced GBM proliferation and kept these cells under undifferentiated state. In contrast, 
mGluR3 inhibition eliminated this constraint and promoted astroglial differentiation [68, 73, 76, 78]. (6) Accordingly to Arcella et al. 
(2005) [73] and Ciceroni et al. (2013) [77], MAPK axis supported mGluR3-induced GBM proliferation, (7) since mGluR3 stimulation 
increased Erk1/2 phosphorylation and its blockade reduced p-Erk1/2 levels. mGluR3 inhibition plus MEK1/2 blockade showed an additive 
antiproliferative effect on GBM cells [68]. (8) Moreover, mGluR3-dependet activation of MAPK pathway limited SMAD1/5/8-induced 
astroglial differentiation, which kept GBM cells under undifferentiated state. Exogenous SMAD1/5/8 stimulation or MEK inhibition 
prevented this effect [76]. (9) mGluR3 activation stimulated (10) phosphorylation of Akt/PKB via PI3K activation and this effect was 
reversed by receptor inhibition [73, 77]. (11) mGluR3-PI3K axis activation presented a permissive role on GBM cell cycle progression, 
since mGluR3 inhibition by LY341495 decreased cyclin D1/D2 immunocontent [68, 73], an early marker of G1/S phase transition [79]. 
(12) mGluR3-PI3K axis was also related to GBM chemoresistance. GSC become sensitive to TMZ, an alkylating agent, only if mGluR3 
was inhibited or silenced [77], which was also mimicked by PI3K blockade. NF-κB activation by Akt/PKB limits pro-apoptotic activity 
of alkylating agents in GBM cells [100]. TMZ increased levels of p-IκB and this effect was reversed by mGluR3 or PI3K blockers. NF-
κB bockade enabled TMZ toxicity, occluding permissive action of mGluR3 inhibition, indicating NF-κB lies downstream of Akt/PKB in 
pathway that restrains TMZ toxicity. (13) Akt/PKB also regulates mTOR, which promotes mRNA translation and protein synthesis through 
p70 S6K and 4E-BP1 phosphorylation [103]. This signaling pathway was showed to support GBM cells survival [106]. (14) Concomitant 
activation of EGFR and mGluR3 could act synergistically in GBM aggressiveness, since simultaneous inhibition of these receptors caused 
maximum apoptosis in GBM cells, as well as reduced their migration. (15) mGluR1 stimulation promoted GBM cells survival through 
PI3K-Akt/PKB-mTOR pathway activation [41]. mGluR1 inhibition markedly decreased cell viability and inhibited PI3K and Akt/PKB 
phosphorylation. mGluR1 inhibition also decreased levels of p-mTOR and P70 S6K
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ligand-gated ion channels, and metabotropic glutamate 
receptors (mGluR), which are coupled to G proteins 
[35, 36]. mGluR family comprises eight subtypes 
subdivided in three groups according to their sequence 
homology, pharmacology, and associated-signaling 
pathway. Group I mGluR are coupled to Gq proteins and 
their activation stimulates phospholipase C (PLC) and 
phosphatidylinositol 4,5-biphosphate (PIP
2
) hydrolysis. 
PIP
2
 hydrolysis generates inositol (1,4,5)-trisphosphate 
(IP
3
) and diacylglycerol (DAG), which stimulates 
intracellular Ca2+ release from endoplasmic reticulum 
and activates protein kinase C (PKC), respectively 
[33]. In contrast, mGluR of group II and III are coupled 
predominantly to Gi/o proteins, inhibiting adenylyl cyclase 
(AC) and, thus, decreasing ion channel activity and other 
downstream signaling pathways [37, 38] (Figure 2). 
Table 1A: RNA expression of group I mGluR subtypes in cellular malignant glioma models.
Metabotropic glutamate 
receptors
mRNA
Sample Expression Reference
Group I
mGluR1
Human Glioma Lineage
U-87 MG
Yes [72]
No [73]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) Yes [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) No [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB4 (Glioblastoma) Yes [48]
GB3 (Glioblastoma) Yes [48]
GB2 (Glioblastoma) Yes [48]
GB1 (Glioblastoma) No [48]
mGluR5
Human Glioma Lineage
U-87 MG
Yes [72]
No [73, 74]
U-343 Yes [72]
MOGGCCM Yes [72]
U-178 MG Yes [74]
U-251 No [68]
Primary culture from 
human glioma
FCN-9 No [68]
MZC-12 No [68]
CDR-97 No [68]
Resection
Anaplastic astrocytoma (52 years old) No [79]
Astrocytoma grade II  (12 years old) Yes [79]
Glioblastoma (53 years old) No [79]
Glioblastoma  (68 years old) No [79]
Glioblastoma  (82 years old) No [79]
Glioblastoma  (58 years old) No [79]
Glioblastoma  (55 years old) No [79]
Astrocytoma grade I  (38 years old) No [79]
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) No [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) No [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB4 (Glioblastoma) Yes [48]
GB3 (Glioblastoma) Yes [48]
GB2 (Glioblastoma) Yes [48]
GB1 (Glioblastoma) Yes [48]
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Table 1B: RNA expression of group II mGluR subtypes in cellular malignant glioma models.
Metabotropic glutamate 
receptors
mRNA
Sample Expression Reference
Group II
mGluR2
Human Glioma Lineage
U-87 MG Yes [72, 73]
U-343 Yes [72]
MOGGCCM Yes [72]
U-251 Yes [68]
Primary culture from 
human glioma
FCN-9 No [68]
MZC-12 and MSS-5 Yes [68]
FLS-10 No [68]
LTN-12 No [68]
BRT-3 No [68]
CRL-8 No [68]
CDR-97 No [68]
Glioma Stem Cells No [76-78]
Resection
Glioblastoma Yes [78]
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) Yes [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB1, GB2, GB3 and GB4 (Glioblastomas) Yes [48]
mGluR3
Human Glioma Lineage
U-87 MG Yes [72, 73]
U-343 No [72]
MOGGCCM Yes [72]
U-251 Yes [68]
Primary culture from 
human glioma
FCN-9 Yes [68]
MZC-12 Yes [68]
FLS-10, LTN-12 and CDR-97 No [68]
MSS-5 Yes [68]
BRT-3 Yes [68]
CRL-8 Yes [68]
Glioma Stem Cells Yes [76-78]
Resection
Glioblastoma Yes [78]
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) Yes [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB1, GB3 and GB4 (Glioblastomas) Yes [48]
GB2 (Glioblastoma) No [48]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) No [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB1, GB3 and GB4 (Glioblastomas) Yes [48]
GB2 (Glioblastoma) No [48]
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Table 1C: RNA expression of group III mGluR subtypes in cellular malignant glioma models.
Metabotropic glutamate 
receptors
mRNA
Sample Expression Reference
Group 
III
mGluR4
Human Glioma Lineage
U-87 MG No [72, 73]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) Yes [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) No [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) No [48]
AZ2 (Low grade astrocytoma) No [48]
GB1, GB2, GB3 and GB4 (Glioblastoma) Yes [48]
mGluR6
Human Glioma Lineage
U-87 MG Yes [72]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) No [48]
AZ7 (Low grade astrocytoma) No [48]
AZ6 (Low grade astrocytoma) No [48]
AZ5 (Low grade astrocytoma) No [48]
AZ4 (Low grade astrocytoma) No [48]
AZ3 (Low grade astrocytoma) No [48]
AZ2 (Low grade astrocytoma) No [48]
GB4 (Glioblastoma) Yes [48]
GB3 (Glioblastoma) Yes [48]
GB2 (Glioblastoma) Yes [48]
GB1 (Glioblastoma) No [48]
mGluR7
Human Glioma Lineage
U-87 MG
Yes [72]
No [73]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) Yes [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) No [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB1, GB2, GB3 and GB4 (Glioblastoma) Yes [48]
mGluR8
Human Glioma Lineage
U-87 MG Yes [72]
U-343 Yes [72]
MOGGCCM Yes [72]
Resection
AZ21 (Low grade astrocytoma) Yes [48]
AZ8 (Low grade astrocytoma) No [48]
AZ7 (Low grade astrocytoma) Yes [48]
AZ6 (Low grade astrocytoma) Yes [48]
AZ5 (Low grade astrocytoma) Yes [48]
AZ4 (Low grade astrocytoma) Yes [48]
AZ3 (Low grade astrocytoma) Yes [48]
AZ2 (Low grade astrocytoma) Yes [48]
GB1, GB3 and GB4 (Glioblastoma) Yes [48]
GB2 (Glioblastoma) No [48]
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Beyond the well-established role of glutamate receptors 
in glutamatergic neurotransmission, several evidences are 
emerging regarding the role of these receptors in cancer 
biology, especially in malignant brain tumors [39-41].
Activation of a mutated Ca+2-permeable form of 
AMPA receptors (AMPAR) enhanced migration and 
proliferation of high-grade gliomas (Figure 1, step 4). 
Blockage of AMPAR by NBQX led to inhibition of 
glioma growth and induced apoptosis of remaining cells 
[42, 43]. AMPAR-mediated tumor proliferation seemed to 
involve a Ca2+-dependent activation of Akt/PKB signaling 
pathway [44], since both NBQX (AMPAR antagonist) 
and Wortmannin (specific inhibitor of PI3K) reduced the 
Akt/PKB phosphorylation and decreased the number of 
tumoral viable cells in culture [45].
Parallel to iGluR, several evidences have 
demonstrated that mGluR are also functionally important 
for proliferation and differentiation of distinct types of 
cancer, including GBM [46]. Group III mGluR is involved 
in malignancy of a lot of cancers [47]. The implication of 
mGluR7 in tumor formation has yet to be characterized 
[46]. mGluR6 gene expression was shown to correlate 
with higher-grade pediatric CNS tumors [48]. Increased 
expression of mGluR4 and mGluR8 was reported in 
human lung adenocarcinoma samples and lung carcinoma 
cell line and treatment with mGluR8 agonist reduced 
cell growth and increased apoptosis in this lineage [49]. 
mGluR4 is overexpressed in more than 40% of malignant 
melanomas, laryngeal squamous cell carcinomas, and 
breast carcinomas and its overexpression was correlated 
with increased mortality in colorectal carcinoma [50]. 
mGluR4 inhibition suppressed proliferation of mGluR4-
expressing colon cancer cell lines [50] whereas mGluR4 
activation reduced cell proliferation in medulloblastoma 
cell lines and inhibits medulloblastoma cell xenografts 
progression in nude mice [51]. In addition, approximately 
77% of human medulloblastoma samples expressed 
mGluR4, which was inversely correlated with tumor 
severity, spread, and recurrence [51]. 
Among Group I mGluR, increased mGluR5 
immunoreactivity in human oral squamous cell 
carcinomas is associated with improved overall survival 
[52]. mGluR5 antagonist reduced tumor cell migration, 
invasion, and adhesion in human tongue cancer cells 
[52] and inhibits cell proliferation of laryngeal cancer 
[53]. Additionally, mGluR5 overexpression has been 
shown to induce melanoma development in transgenic 
mice [54]. Ectopic expression of mGluR1 in normal 
melanocytes induced melanocyte hyperproliferation in 
vitro and promote melanoma tumor development in vivo 
[55-59]. mGluR1 expression has been widely explored in 
breast cancer, supporting angiogenesis in these tumors, 
and silencing of this receptor (GRM1 shRNA) resulted in 
inhibition of cell proliferation [60]. In addition, mutations 
and single nucleotide polymorphisms (SNPs) of GRM1 
were described in prostate cancer [61] and eight somatic 
variations of GRM1 were identified in cancers, including 
lung adenocarcinoma [62]. Group II mGluR is also 
implicated in a variety of cancer types [47], including 
melanoma [63]. Both group I and II mGluR are involved 
in glioma progression and the action in vitro and in vivo of 
agonists and antagonists of these receptors will be reported 
in detail in this review.
The above-mentioned evidences indicate that group 
I and III mGluR may be considered a potential therapeutic 
target for both gliomas and other forms of cancer. 
Moreover, from physiological and pharmacological 
point of view, there is a growing number of evidences 
suggesting mGluR are better drug targets than iGluR 
[64-67]. Compared to iGluR, mGluR play a ‘modulatory’ 
rather than ‘mediatory’ role in glutamatergic excitatory 
synaptic transmission [68-71]. Consequently, mGluR 
ligands (such as agonists or antagonists) might lead to 
more subtle effects on fast excitatory transmission than 
iGluR antagonists, which indicates their therapeutic use 
may be more tolerable for patients [64, 65].
IN VITRO STUDIES EVALUATING 
THE ROLE OF mGluR ON GLIOMA 
PROLIFERATION
Glioma cell cultures have been widely used to 
elucidate the role of mGluR in cancer malignancy. Some 
studies have used GBM lineages as cellular model [68, 
72-75] while others have used primary cultures from 
human GBM resections [68, 76-79]. Table 1 (A, B and 
C) and Table 2 summarizes current literature evaluating 
mRNA expression and protein immunocontent of mGluR, 
respectively, in glioma cultures and human glioma 
resections. Group II mGluR (mGluR2/3) was the most 
investigated (expressed - mRNA - and immunodetected - 
protein) in the majority of human glioma biopsy samples, 
primary cultures, and glioma lineages. In order to clarify 
the role of mGluR on proliferation, invasiveness, and 
migration, several assays were performed treating GBM 
cells with antagonists and/or agonists of these receptors. 
Arcella et al. (2005) showed pharmacological 
blockade of mGluR2/3 induced antiproliferative effects in 
U-87 MG glioma cell line. Daily addition (four days) of 
mGluR2/3 antagonists (LY 341495 - 1 µM; MTPG - 100 
µM; or EGLU - 100 µM) to U-87 MG cultures reduced 
cell proliferation in a time-dependent manner, while did 
not induce apoptosis [73] (Figure 1, step 5). However, 
this treatment altered cell cycle, since FACS analysis 
showed antagonist reduced percentage of cells in S and 
G2M phases after two but not after four days of exposure. 
Furthermore, in cultures deprived of serum by 72 h, 
LY 341495 treatment reduced EGF-induced cyclin D1/
D2 protein expression (early marker of the G1/S phase 
transition [79]).
In another study, using primary cultures from 
human GBM biopsies, D’Onofrio et al. (2003) showed 
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pharmacological blockade of mGluR3 reduced cell 
proliferation [68]. This effect was observed in all selected 
cultures mGluR3+. Application of antagonist LY 341495 
(1 µM) to growing medium once a day (for four days) 
reduced linear phase of growth in mGluR3+ cultures, 
with cell number being substantially reduced at 4th day 
of treatment. Cell growth was restored two days after 
washing out LY 341495, indicating that antiproliferative 
effect was reversible (i.e., antagonist was cytostatic, not 
cytotoxic). For excluding involvement of other mGluR, 
authors performed an additional experiment using lower 
concentrations of LY 341495 and this antagonist was able 
to reduce linearly cell growth at concentrations of 1 and 10 
nM, indicating that inhibition of mGluR3 was responsible 
for antiproliferative effect of LY 341495. This result was 
further corroborated by evidence that EGLU (100 µM), 
another antagonist of mGluR3, mimicked LY 341495 
action on cell growth.
Glioma stem cells (GSC) are brain tumor-initiating 
undifferentiated cells [80], which have multipotential 
differentiation capacity, high tumorigenic potential 
and low proliferation rate [81, 82]. Normally, GSC are 
obtained from adult human GBM biopsy samples and 
form in culture classical floating aggregates, named 
tumor spheres. These cells are very chemoresistant and 
radioresistant and therefore probably responsible for 
tumor progression and recurrence after conventional 
GBM resection [82]. Ciceroni et al. (2008) and Zhou et 
al. (2014) observed GSC express mGluR3 protein (but 
not mGluR2) and its pharmacological blockade promoted 
an astroglial differentiation of GSC [76, 78]. Zhou et al. 
(2014) showed mGluR3 blockade by LY 341495 (100 nM) 
for 48 h resulted in a decreased proliferation combined 
with an increase in GSC GFAP+ cells (classical marker 
for mature astrocytes) and a decrease of GSC nestin+ cells 
(classical marker for neural stem cells) [78]. In addition, 
stimulation of mGluR3 for 48 h by specific agonist LY 
379268 (100 nM) has no effect on GSC proliferation 
and differentiation, which suggests mGluR3 activity is 
necessary to maintain proliferation but is incapable of 
stimulating it per se (Figure 1, step 5).
Ciceroni et al. (2008) showed treatment of GSC 
with antagonist LY 341495 (100 nM) promoted astrocytic-
like differentiation of cells (increasing GFAP+ cells) 
and nestin+ cells were virtually absent after 14 days of 
treatment [76]. Treatment with agonist LY 379268 (100 
nM) did not affect differentiation of cells. In another 
set of experiments, these authors cultured GSC under 
differentiating conditions (medium deprived of mitogens 
and containing 10% of fetal calf serum) for 8 days and 
received treatments with mGluR3 ligants. After, cells were 
enzymatically dissociated, transferred to uncoated 96-well 
plates, and regrown under proliferating conditions without 
any mGluR3 ligants (medium containing epidermal 
growth factor - EGF - plus basic fibroblast growth factor 
- bFGF - and lacking serum) for plus 12 days. Treatment 
of cells with agonist LY 379268 during differentiation 
phase led to formation of tumor spheres in proliferative 
phase. In contrast, cells treated with antagonist LY 341495 
originated cultures containing exclusively adherent 
astrocyte-like cells. This indicated that treatment with 
mGluR3 antagonist was sufficient to maintain GSC 
towards astroglial differentiation even under conditions 
in which they normally proliferate and maintain their 
undifferentiated state (Figure 1, step 5).
For both above-mentioned studies [76, 78], 
GSC did not respond to agonist LY 379268 probably 
because mGluR3 were constantly stimulated by L-Glu 
already present in culture medium. Concentrations of 
extracellular L-Glu in GSC cultured for 8 and 14 days 
under differentiating conditions (medium deprived of 
mitogens and containing serum) were about 60 µM and 
70 µM, respectively [76]. These concentrations exceed the 
reported EC
50
 value for L-Glu and recombinant mGluR3 
by 5-10 fold [83], which is sufficient to saturate all 
mGluR3.These results point to the notion that activation 
of mGluR3 by endogenous L-Glu allows proliferation of 
GSC by limiting astroglial differentiation and that receptor 
blockage eliminates this constraint, thereby promoting 
cell differentiation. This hypothesis is supported by work 
performed by Yelskaya et al. (2013), in which U-87 
MG cultures where treated with Riluzole (1-100 µM), a 
drug that blocks the secretion of L-Glu and enhances its 
uptake from extracellular space [47]. Riluzole inhibited 
proliferation of cells in a dose-dependent manner, 
suggesting that absence of L-Glu in extracellular medium 
prevents glutamate-dependent proliferation and putative 
activation of mGluR3 in U-87 MG cells [84].
Group II mGluR are known to be able to activate 
the MAPK and PI3K pathways [37, 85-89], which are 
usually activated in response to proliferating agents 
[90, 91]. Arcella et al. (2005) [73] showed treatment of 
U-87 MG cultures with antagonist LY 341495 (1 µM) 
reduced activation of MAPK (assessed by WB analysis 
of p-Erk1/2) and PI3K (assessed by WB analysis of 
p-Akt/PKB) pathways. All of these effects were reversed 
by addition of agonist LY 379268 (1 µM), which was 
inactive per se. WB analysis also showed exposure to LY 
341495 did not alter mGluR2/3 immunocontent (at least 
up to four days of treatment). Another study indicated 
that activation of mGluR3 could have a permissive role 
on stimulation of MAPK and PI3K pathways in GSCs 
dissociated cultures [77]. GSCs dissociated from tumor 
spheres were starved from mitogens and then treated with 
agonist LY 379268 (100 nM), which inhibited forskolin-
stimulated cyclic adenosine monophosphate (cAMP) 
formation and increased p-Erk1/2 and p-Akt/PKB levels. 
All these effects were reversed by antagonist LY341495 
(100 nM). In addition, treatment with LY 341495 also 
reversed EGF- and bFGF-induced increase in p-Erk1/2 
and p-Akt/PKB levels. LY 341495 alone did not affect 
EGF receptor (EGFR) autophosphorylation in response to 
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EGF, which suggests that this drug had no direct effects on 
EGFR (Figure 1, step 6, 7, 9 and 10).
D’Onofrio et al (2003) examined the immunocontent 
of cyclin D1 and D2 and the activation of MAPK 
pathway in primary GBM cell cultures in serum-deprived 
conditions and in proliferative conditions (cells incubated 
with EGF for 8 h, for assessment of cyclin D1/D2, or 
for 10 min, for assessment of MAPK pathway) [68]. 
Addition of 1 µM of mGluR3 antagonist LY 341495 (in 
combination with EGF) reduced EGF-induced increase 
in immunocontent of both cyclin D1/D2 and p-Erk1/2. 
Effect on cyclin D1/D2 protein expression was partially 
reversed by agonist LY 379268 (1 µM) (Figure 1, step 11). 
To assess whether inhibition of MAPK pathway was the 
only mechanism responsible for antiproliferative effect 
of LY 341495, authors studied association of this drug 
with MAPK kinase (MEK) inhibitor, PD 98059. Both 
LY 341495 (1 µM) and PD 98059 (30 µM) reduced cell 
number in about 45%. Ability of LY 341495 and PD 98059 
to reduce Erk1/2 phosphorylation suggests mGluR2/3-
MAPK axis supports proliferation rate of human GBM 
cells. Since anti-proliferative effect of LY 341495 was 
not totally obliterated by PD 98059, other proliferation 
pathways may be also being controlled by mGluR2/3 in 
GBM cells (Figure 1, step 6 and 7).
Ciceroni et al. (2008) focused on interaction between 
mGluR3 and bone morphogenetic proteins (BMP), 
which are known to promote astroglial differentiation of 
GSC [92]. BMP bind to membrane receptors of BMP/
TGF-ß/activin family, which leads to phosphorylation 
and translocation of Smad1/5/8 proteins to nucleus [93]. 
Addition of exogenous BMP4 (100 ng/mL) plus mGluR3 
agonist LY 379268 (100 nM) prevented BMP4-induced 
nuclear translocation and phosphorylation of Smad. 
Inhibitory action of LY 379268 was unaffected by non-
metabolizable cAMP analogue, 8-Bromo-cAMP (1 mM), 
but was prevented by MAPK kinase (MEK) inhibitor, 
UO126 (30 µM), which was inactive per se. Moreover, 
cultures exposed to mGluR3 antagonist LY 341495 (100 
nM) enhanced Smad1/5/8 phosphorylation to an extent 
similar to BMP4. These results suggested that activation 
of mGluR3 could inhibit BMP4 receptor signaling by 
activation of MAPK pathway. In addition, activation of 
mGluR3-MAPK pathway by endogenous L-Glu presented 
in medium may limit BMP4-induced differentiating 
activity, thus contributing to support undifferentiated state 
of GSCs, and eventually GBM growth and relapse [76] 
(Figure 1, step 8).
Yelskaya et al. (2013) reported that a combination of 
mGluR2/3 antagonist LY 341495 and Gefitinib, an EGFR 
inhibitor, works most efficiently to inhibit proliferation 
and migration of U-87 MG cells and induced apoptosis 
in this cell lineage [84]. They also investigated the 
efficacy of different classes of drugs (AMPAR antagonist 
- NBQX; mGluR2/3 antagonist - LY341495; EGFR 
inhibitor - Gefitinib; and PI3K inhibitors - Wortmannin 
and PI 828) in inhibiting proliferation of U-87 MG cells 
(24 h). A combination of Gefitinib (25 µM) with LY 
341495 (1 µM) or PI 828 (2 µM) was more effective to 
inhibit proliferation of U-87 MG cells when compared 
to individual drugs alone. Using TUNEL assay, authors 
showed treatment with Gefitinib resulted in increased 
apoptosis compared to control group. Gefitinib in 
combination with PI 828 or Wortmannin (5 µM) did not 
increase apoptosis in cell cultures. However, treatment 
with Gefitinib plus NBQX (5 µM) or Gefitinib plus LY 
341495 increased apoptosis compared to Gefitinib, NBQX 
or LY 341495 alone. Maximum percentage of apoptosis 
was observed in treatment with Gefitinib plus LY341495. 
Distance migrated by cells (wound healing assay) was 
significantly reduced with Gefitinib plus LY 341495 
treatment when compared to treatments with Gefitinib or 
LY 341495 alone or control group (Figure 1, step 14). 
An interesting question that arises from above-
mentioned works is whether mGluR3 antagonists could 
interact with classical chemotherapies and whether 
activation of this receptor in malignant gliomas 
could control expression of proteins implicated in 
chemoresistance. In this context, Ciceroni et al. (2013) 
showed mGluR3 inhibition enables cytotoxic action of 
TMZ in GSC cultures [77]. TMZ (250 µM) did not affect 
cell viability when applied alone, but became toxic when 
combined with LY 341495 (100 nM) and LY 2389575 
(100 nM), two mGluR3 antagonists. mGluR3 agonist 
LY 379268 (100 nM) was inactive per se, but reversed 
the permissive action of LY 341495 on TMZ toxicity. 
siRNA-induced knockdown of mGluR3 also enabled TMZ 
toxicity and antagonist LY 341495 did not further amplify 
TMZ toxicity in mGluR3 silenced cells [77]. This data 
suggests that a possible activation of mGluR3 by GSC-
autocrine release of L-Glu could restrain toxic action of 
TMZ, increasing chemoresistance of these tumor cells 
(Figure 1, step 12). GSC were treated with other anticancer 
drugs (etoposide, irinotecan, irinotecan metabolite - 
SN 38, cisplatin or paclitaxel) alone or combined with 
mGluR3 antagonist LY341495 and these treatments had 
no significant effect on GSC viability, suggesting mGluR3 
receptors selectively control responses of cells to TMZ and 
could not be extended to other chemotherapeutic agents.
In order to evaluate mechanisms underlying 
mGluR3-induced chemoresistance, Ciceroni et al. (2013) 
treated GSC with molecules that interfere in three major 
signaling pathways activated by mGluR3 [77]: inhibition 
of adenylyl cyclase (AC) activity, activation of MAPK 
pathway and activation of PI3K pathway [85, 88, 94, 
95]. Cell permeable cAMP analog, 8-Bromo-cAMP (1 
mM), did not affect synergism between mGluR3 blockade 
and TMZ. MAPK kinase (MEK) inhibitor, UO126 (30 
µM), had mild effect on TMZ toxicity. In contrast, PI3K 
inhibitor LY 294002 (10 µM) had a permissive action on 
TMZ toxicity, mimicking the effect of mGluR3 blockade. 
Actions of LY 294002 and LY 341495 were less than 
Oncotarget22288www.impactjournals.com/oncotarget
addictive, suggesting mGluR3 inhibition facilitates 
cytotoxicity by limiting activation of PI3K pathway. This 
hypothesis was supported by the use of GSCs expressing 
a constitutively active form of t PI3K substrate, Akt/PKB 
[96]. In these cells, in which PI3K pathway was active in 
spite of mGluR3 blockade, synergism between LY 341495 
and TMZ was largely attenuated (Figure 1, step 12).
The sensitivity of cancer cell lineages to various 
inhibitors and chemotherapeutic drugs is often associated 
with genetic mutations of key elements in the Ras-
Raf-MEK-ERK and PI3K-PTEN-Akt/PKB-mTOR 
pathways [97, 98]. Akt/PKB is known to activate nuclear 
factor-κB (NF-κB) by phosphorylating IκB kinase 
[99], which limits the pro-apoptotic activity of DNA-
alkylating agents in glioma cells [100]. In Ciceroni et 
al. (2013) study, treatment with TMZ activated NF-κB, 
showed by increased levels of IκB phosphorylation. 
This effect was reversed by mGluR3 antagonist, LY 
341495, or by PI3K inhibitor, LY 294002. The specific 
NF-κB inhibitor JSH-23 (10 µM) [101] enabled TMZ 
toxicity and occluded permissive action of LY 341495 
in GSCs. Similar effects were obtained with salicylic 
acid, which also inhibits NF-κB [102]. As opposed to 
LY 341495, JSH-23 could still enhance TMZ toxicity in 
GSCs expressing the constitutively active form of Akt/
PKB, indicating NF-κB lies downstream to Akt/PKB in 
pathway that restrains TMZ toxicity (Figure 1, step 12). 
Akt/PKB also regulates mammalian target of rapamycin 
(mTOR), which promotes mRNA translation and protein 
synthesis by phosphorylating p70 S6K and 4E-BP1 [103]. 
Figure 2: Downstream signaling pathways activated by metabotropic glutamate receptors (mGluR). mGluR family 
comprises eight subtypes subdivided in three groups according their sequence homology, pharmacology, and second messenger 
signaling pathway association. Group I mGluR are coupled to Gq proteins and their activation stimulates phospholipase C (PLC) and 
phosphatidylinositol 4,5-biphosphate (PIP
2
) hydrolysis. PIP
2
 hydrolysis generates inositol (1,4,5)-trisphosphate (IP
3
) and diacylglycerol 
(DAG), which stimulates intracellular Ca2+ release from endoplasmic reticulum and activates protein kinase C (PKC), respectively. In 
contrast, mGluR of group II and III are coupled predominantly to Gi/o proteins and classically related to inhibition of adenylyl cyclase (AC) 
and directly regulate ion channel activity and other downstream signaling partners via liberation of G
βγ
 subunits.
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mGluR stimulation activates mTOR pathway [104, 105] 
and inhibitors of Akt/PKB-mTOR pathway are under 
development for treatment of cancer, including malignant 
gliomas [106, 107]. In Ciceroni et al. (2013) work, it was 
shown selective mTOR inhibitor rapamycin (10 nM) 
did not mimic, but rather abolished permissive action of 
mGluR3 blockade on TMZ toxicity (Figure 1, step 13).
Clinical efficacy of TMZ is limited by 
DNA-repairing enzyme, O6-methylguanine-DNA 
methyltransferase (MGMT), which removes DNA adducts 
generated by alkylating agents [108]. In Ciceroni et al. 
(2013) [77] study, GSC clones constitutively expressed 
MGMT and treatment with TMZ alone increased MGMT 
mRNA levels 3 h after its application and slightly reduced 
MGMT protein levels at 24 and 48 h. When TMZ was 
combined with LY 341495, MGMT mRNA did not 
increase and MGMT protein levels were markedly 
reduced. Moreover, action of LY341495 was mimicked by 
siRNA-induced knockdown of mGluR3, or PI3K inhibitor 
(LY 294002), or by NF-κB inhibitor (JSH-23). Finally, 
the permissive action of LY 341495, LY 294002, or JSH-
23 was no longer seen in GSC overexpressing MGMT, 
demonstrating that synergistic action of mGluR3 blockade 
and TMZ treatment was mediated by inhibition of MGMT 
expression. This hypothesis was supported by evidence 
that treatment with MGMT inhibitor, O6-benzylguanine 
(10 µM), enabled TMZ toxicity. These results suggest that 
mGluR3-dependent TMZ toxicity restrains is supported 
by induction of MGMT transcription via an intracellular 
signaling pathway that sequentially involves PI3K and 
NF-κB.
A recent study described, for the first time, an anti-
cancer role of mGluR1 in gliomas [41]. Zhang et al. (2015) 
showed treatment with selective mGluR1 antagonist Bay 
36-7620 (50µM) or Riluzole (50µM), a glutamate release 
inhibitor approved for amyotrophic lateral sclerosis [47, 
109], markedly decreased cell viability and increased LDH 
release in U-87 MG lineage. These treatments and mGluR1 
knockdown (using siRNA technology) significantly 
increased apoptotic rate in these glioma cells. In addition, 
Figure 3: In vivo models employed to study the role of mGluR on brain tumor growth and aggressiveness. A. and B. 
Effects of mGluR ligands in two mice xenograft models. C. Relation between tumoral mGluR3 mRNA expression and GBM patients’ 
survival.
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Riluzole or Bay 36-7620 increased immunocontent of 
cleaved PARP and caspase-3, whereas immunocontent 
of pro-PARP and pro-caspase-3 was not altered. Similar 
results were observed after mGluR1 knockdown. Authors 
also tested whether treatment with Riluzole or Bay 36-
7620 and transfection with mGluR1 targeted siRNA could 
induce inhibition of PI3K activity in U87 cells. U-87 MG 
cells showed a significantly decreased phosphorylation 
of PI3K after mGluR1 blockade as well as after mGluR1 
targeted siRNA. mGluR1-dependent inhibition of PI3K 
resulted in inhibition of Akt/PKB phosphorylation at 
both Ser473 and Thr308 residues. Moreover, mGluR1 
inhibition decreased expression levels of p-mTOR and 
P70 S6K, one of the best-characterized targets of mTOR 
complex. In contrast, expression of PTEN was not 
changed by antagonists or siRNA transfection. All these 
data provided strong evidence that activation of PI3K-
Akt/PKB-mTOR pathway was suppressed after mGluR1 
inhibition (Figure 1, step 15). 
The majority of above-mentioned in vitro works 
indicates that endogenous activation of mGluR1 and 
mGluR3 increase the proliferation of GBM cells and 
that MAPK and PI3K pathways may be involved in this 
process. All of these studies are particularly interesting 
from a therapeutic standpoint since ligands of these types 
of mGluR represent an expanding class of drugs endowed 
with high receptor affinity, elevated brain penetration, 
and good profile of safety and tolerability [65, 83]. These 
features make these drugs potential candidates for in vivo 
studies evaluating progression and aggressiveness of 
malignant brain tumors.
IN VIVO STUDIES EVALUATING THE 
ROLE OF mGluR ON GLIOMA TUMOR 
PROGRESSION
Arcella et al. (2005) [73] have shown that a 
continuous systemic infusion of mGluR2/3 antagonist LY 
341495 reduced growth of GBM cells in two independent 
in vivo models. U-87 MG cells were implanted under skin 
(2 x 106 cells/mL) of mice, which were subcutaneously 
implanted with osmotic minipumps releasing saline, LY 
341495 (1 mg/kg per day), EGLU (1 mg/kg per day), LY 
379268 (1 mg/kg per day), or LY 341495 plus LY 379268 
during 28 days. Analysis of tumor weight showed chronic 
infusion of antagonists LY 341495 or EGLU reduced 
GBM growth. On the other hand, infusion of mGluR2/3 
agonist LY 379268 did not affect tumor growth and failed 
to fully reverse LY341495 effect. These results corroborate 
with Zhou et al. (2014) in vitro study [78], in which 
activation of mGluR2/3-dependent signaling pathway is 
necessary to maintain tumor growth but is incapable of 
stimulating it per se.
In another set of experiments, Arcella et al. (2005) 
implanted U-87 MG cells into brain left caudate nucleus 
of nude mice and immunohistochemical analysis revealed 
that these cells showed a higher expression of mGluR2/3 
and Ki-67 (a cellular marker for proliferation) [73]. After 
magnetic resonance imaging (MRI) analysis (7th day after 
cell implantation), selected mice with similar tumor sizes 
were subcutaneously implanted with osmotic minipumps 
releasing either saline or antagonist LY 341495 (10 mg/kg 
per day). Treatment during 7 days with LY 341495 reduced 
tumor size and drug effect was particularly evident 
during exponential phase of tumor growth (between the 
21st and 28th days after cell implantation). Withdrawal 
of LY 341495 on 21st day allowed growing of tumor to 
the same extent as control group, suggesting effect of LY 
341495 was reversible and cytostatic. Treatment with LY 
341495 also reduced the number of Ki-67+ cells in tumor 
specimens.
These two xenograft models above-described 
may be complementary (Figure 3A and 3B). Growth 
of implanted cells in a soft tissue (i.e., subcutaneously) 
evaluates mainly proliferation rate of tumor on an 
adequate energy supply. On the other hand, growth of 
glioma cells in brain requires multiple processes, such 
as excitotoxic-mediated neuronal death, expression of 
enzymes that degrade extracellular matrix, and expression 
of ion channels that drive movement of water out of 
cell [110]. Unfortunately, work performed by Arcella 
et al. (2005) have no information regarding outcome of 
mice treated with LY 341495, since animals were not 
allowed to survive beyond the 4th week of tumor growth. 
Nevertheless, authors said none of the five mice died 
during the four weeks of observation in group treated with 
this antagonist [73].
Ciceroni et al. (2008) showed continuous 
pharmacological blockade of mGluR3 reduced growth 
of infiltrating brain tumors originating from GSC 
xenografts [76]. GSC spheres were suspended in their 
growing medium and then infused into left striatum of 
nude mice (3 x 105 cells/3 µL). Immediately after cell 
transplantation, mice were subcutaneously implanted 
with osmotic minipumps releasing mGluR3 agonist LY 
379268 or antagonist LY 341495 (both at a rate of 1 mg/
kg per day during 3 months), or filled with saline solution. 
MRI analysis carried out at 3 months showed signal 
alterations in brain parenchyma of control and LY 379268 
treated mice, however, no changes were observed in mice 
treated with antagonist LY 341495. Histological analysis 
revealed presence of small and large aggregates of GBM 
cells in brain parenchyma, which were characterized by 
nuclear atypia and high mitotic activity. These features 
are consistent with primitive advanced-stage GBM, 
where tumors migrate and disseminate asymmetrically 
along blood vessels and fiber tracts and not grow 
uniformly [111]. Cell aggregates were consistently found 
in ipsilateral neostriatum, as well as along the intra- and 
inter-hemispheric white matter in both control and LY 
379268 treated mice. On the other hand, aggregates were 
absent or present to a very low extent in animals treated 
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with antagonist LY 341495, which indicates that mGluR3 
blockage inhibited GSC-dependent generation of tumor 
cell progeny and/or reduced the growth of GBM malignant 
cells.
Zhou et al. (2014) used a model of subcutaneous 
implantation of GSC (1x103 cells) in right axilla of mice 
[78]. After 3 weeks of GSC implantation, tumors were 
large, ulcerative and had complete capsule. HE stained 
reveled cells with dark nuclei without evidences of 
necrosis. Intercellular heteromorphism was obvious and 
vascular structure was clear. Mice treated with LY 341495 
intraperitoneally (1 mg/kg per day) presented a reduced 
tumor volume when compared to animals treated with 
agonist LY 379268 (1 mg/kg per day) and vehicle. This 
result was sustained during 10th, 15th and 20th days after 
cells implantation.
Ciceroni et al. (2013) have evaluated the effect 
of mGluR3 inhibition plus TMZ treatment on tumor 
growth in nude mice implanted with human GSCs in 
brain parenchyma [77]. All mice were subcutaneously 
implanted with osmotic minipumps releasing LY 341495 
antagonist (3mg/kg per day for 28 days) or saline. At 
the same time, mice received three injections of TMZ 
(70mg/kg, intraperitoneally) or vehicle (every day) during 
the 1st week following minipump implantation. In one 
experiment, mice received drug treatments during 15 days 
after GSC implantation and were killed 30 days later (i.e. 
45 days after cell implantation). In the other experiment, 
mice were treated with drugs during 45 days after GSC 
implantation and killed 30 days later (i.e. 75 days after 
cell implantation). Control mice (i.e., minipump releasing 
saline and vehicle injected intraperitoneally) showed 
presence of GSCs in brain with typical morphology of 
GBM. For mice killed 45 days after cell implantation, 
tumor cells were confined to medial portion of caudate 
nucleus close to wall of lateral ventricle. Mice killed at 
75th day showed infiltrating mass tumors in ipsilateral 
caudate nucleus. Moreover, tumor cells spread to ipsi- and 
contralateral portion of corpus callosum. Treatment of 
animals with LY 341495 or TMZ alone did not alter tumor 
Table 2: Protein immunocontent of mGluR subtypes in cellular malignant glioma models.
Metabotropic glutamate 
receptors
Protein (Western Blot)
Sample Expression Reference
Group I
mGluR1
Human Glioma Lineage
U-87 MG Yes [41]
U-373 No [75]
Resection
Astrocytoma II No [75]
Astrocytoma 
Anaplastic No [75]
Glioblastoma No [75]
mGluR5
Human Glioma Lineage
U-87 MG Yes [41, 75]
U-373 Yes [75]
U-118 Yes [75]
Resection
Astrocytoma II Yes [75]
Astrocytoma 
Anaplastic Yes [75]
Glioblastoma Yes [75]
Group II
mGluR2/3
Human Glioma Lineage
U-87 MG Yes [68]
U-373 No [68]
A172 Yes [68]
Primary culture from human 
glioma
FCN-9 Yes [68]
MZC-12 Yes [68]
MSS-5 Yes [68]
BRT-3 Yes [68]
CRL-8 Yes [68]
GSS 98 Yes [68]
DMD 126 Yes [68]
MTR4 Yes [68]
Glioma Stem Cells Yes [76, 77]
Resection
Astrocytoma II Yes [75]
Astrocytoma 
Anaplastic Yes [75]
Glioblastoma Yes [75]
mGluR2
Primary culture from human 
glioma Glioma Stem Cells No [78]
Resection Glioblastoma Yes [78]
mGluR3
Primary culture from human 
glioma Glioma Stem Cells Yes [78]
Resection Glioblastoma Yes [78]
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growth in all analyzed brain areas. However, a combined 
treatment with TMZ plus LY341495 significantly reduced 
tumor growth in analyzed brain areas. The authors did 
not observe any signs of systemic toxicity or motor 
impairment in mice treated with LY 341495 (3 mg/kg 
per day). In addition, in this work mice survived to acute 
experiments using doses higher than 300 mg/kg of LY 
341495.
Zhang et al. (2015) also demonstrated an anti-
tumor activity of mGluR1 inhibition in vivo using a U-87 
MG xenograft GBM model in nude mice [41]. After 
implantation of U-87 MG, tumor-bearing mice were 
treated every day with Bay 36-7620 (mGluR1 antagonist 
- 10 mg/kg) intraperitoneally during 24 days. Treatment 
reduced significantly tumor volume from 22nd to 30th days 
when compared to control group. In other experiment, 
nude mice were injected with si-mGluR1 transfected 
U-87 MG cells or si-control transfected U-87 MG cells. As 
expected, tumor in si-mGluR1 group had a smaller volume 
when compared to si-control group.
Association between antitumoral features and 
apparently non-toxic effects of mGluR antagonists in 
vivo indicates these drugs are potential candidates for an 
adjuvant treatment for GBM in humans.
PATIENTS COHORT TO EVALUATE 
THE ROLE OF mGluR ON GLIOMA 
AGGRESSIVENESS
Only one study has evaluated the profile of mGluR 
mRNA expression in a cohort of patients with GBM 
(Figure 3C) [77]. It was analyzed a possible relationship 
between expression levels of mGluR3 and survival rate 
of patients with GBM undergoing surgery followed by 
radiotherapy and TMZ chemotherapy. The transcript of 
mGluR3 was measured by quantitative PCR in selected 
regions of tumor in a cohort of 87 patients. ‘Normal’ 
mGluR3 mRNA levels were defined as those measured in 
autoptic brain samples with no histological abnormalities. 
Levels of mGluR3 mRNA below normal range were 
detected in 42 GBM biopsies (48.3%), whereas 45 tumor 
samples (51.7%) presented higher mRNA levels. Kaplan-
Meier (KM) survival analysis showed a prolonged survival 
rate for patients with tumoral mGluR3 RNA expression 
below normal range. Interestingly, five patients who 
survived longer than 36 months showed tumoral mGluR3 
mRNA expression below normal range. On multivariate 
analysis, Karnofsky performance score and mGluR3 
mRNA emerged as independent predictors for survival. 
Authors also stratified patients for mGluR3 expression and 
methylation of MGMT promoter. Group with low tumoral 
mGluR3 mRNA levels and methylated MGMT promoter 
showed a significantly higher survival rate as compared to 
low tumoral mGluR3 mRNA and unmethylated MGMT 
promoter group.
In summary, low levels of mGluR3 mRNA in 
tumor specimens may be a predictor for long survival rate 
in patients with GBM. In addition, methylation state of 
MGMT gene promoter influenced survival only in those 
patients whose GBM biopsies presented low expression 
of mGluR3 RNA. These data may encourage the use of 
mGluR3 antagonists as adjuvant drugs for treatment of 
GBM and suggest transcript levels of mGluR3 should be 
a potential predictor of GBM patients’ survival.
CONCLUSIONS
A large number of preclinical studies have suggested 
that metabotropic glutamate receptors could be considered 
a prospective molecular target for treatment of several 
brain disorders, including depression [112], anxiety 
disorders [113], Alzheimer’s disease [114], Parkinson’s 
disease [115], and more recently malignant brain tumors. 
Several in vitro and in vivo studies have supported the 
putative involvement of mGluR-mediated signaling on 
progression, aggressiveness, and recurrence of malignant 
gliomas, which points to the notion that specific subtype-
selective mGluR ligands may be considered as potential 
adjuvant chemotherapy for glioma treatment. Several 
academic groups [116-118], Pfizer [119], Roche [120, 
121], Novartis [122] and Merck [123] have employed 
receptor structure-based design of mGluR selective 
negative allosteric modulators (NAMs) in their studies 
and ligand-receptor binding models were refined using 
mutagenesis and structure-activity data. Even though 
pharmaceutical and toxicological properties of all mGluR 
ligands are not yet entirely determined for humans (such 
as effective and maximum tolerable doses), several clinical 
studies on Phase I, II and III are being performed using 
mGluR modulators for treatment of distinct brain disorders 
and cancer. Addex Pharmaceuticals (Geneva, Switzerland) 
are recently performing a Phase I clinical trials on its 
mGluR5 ligand ADX48621 for the treatment of depression 
and anxiety (ClinicalTrials.gov Identifier: NCT02447640). 
Similarly, a compound LY 2140023, a prodrug of the 
group II metabotropic glutamate receptor agonist LY 
404039, has been tested in a Phase III for the treatment of 
patients with schizophrenia (ClinicalTrials.gov Identifier: 
NCT01328093). Regarding cancer treatment, Barbara 
Ann Karmanos Cancer Institute in collaboration with 
National Cancer Institute (NCI) are performing a Phase 
I clinical trial to evaluated the efficacy of riluzole, a 
mGluR 1 blocker, into reduce the breast cancer growth 
(NCT00903214). If any of these compounds eventually 
obtain approval by the Food and Drug Administration 
(FDA), there will be a strong scientifically-based rationale 
for testing distinct group I and II mGluR antagonists in the 
treatment of malignant brain tumors through prospective, 
large-scale and randomized clinical trials.
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siRNA: Small interfering RNA
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